{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016285","form_type":"8-K","ticker":"IMDX","cik":"0001642380","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.798769+00:00","generated_at":"2026-06-15T04:13:15.954178+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Oncocyte Q1 revenue down 50% to $0.7M; CFO Anish John to leave June 15","bullets":["Revenue $0.7M, down 50% YoY; net operating income $2.9M vs loss of $9.4M.","CFO Anish John departing June 15, 2023; no disagreements; search for replacement.","Completed $13.86M equity raise in April from common stock sale.","R&D expenses $2.8M (-45% YoY); G&A $3.7M (-35%); S&M $1.2M (-63%).","Sold 70% of Razor Genomics; transitioning to capital-light kitted product model."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016285","json":"https://secwatch.observer/filing/0001493152-23-016285.json","markdown":"https://secwatch.observer/filing/0001493152-23-016285.md","text":"https://secwatch.observer/filing/0001493152-23-016285.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223016285/0001493152-23-016285-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223016285/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:13:15.954178+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4b1d9c51ed907676ac8ad89e78442083dad57fc9","claim":"Insight Molecular Diagnostics Inc. reported the three months ended March 31, 2023 results: revenue $0.7 million, net income $2.9 million.","evidence_excerpt":"to create value for both patients and shareholders.” First Quarter 2023 Financial Results Consolidated revenues for the three months ended March 31, 2023, were approximately $0.7 million, a 50% decrease compared to the first quarter of 2022. Excluding DetermaRx revenue, the continuing operations revenue was $0.3 million for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223016285/0001493152-23-016285-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Revenue","value":"$0.7 million"},{"label":"Net income","value":"$2.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"dd54a96d3d","claim":"Anish John resigned as Chief Financial Officer at Insight Molecular Diagnostics Inc..","evidence_excerpt":"On May 11, 2023, Oncocyte announced that Anish John, our Chief Financial Officer, will be leaving the Company on June 15, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223016285/0001493152-23-016285-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}